Literature DB >> 32109056

Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation.

John Liddle1, Jonathan P Hutchinson2, Semra Kitchen1, Paul Rowland2, Margarete Neu2, Ted Cecconie3, Duncan S Holmes1, Emma Jones2, Justyna Korczynska2, Despoina Koumantou4, Jonathan D Lea2, Leng Nickels3, Michelle Pemberton2, Alex Phillipou2, Jessica L Schneck3, Hester Sheehan2, Christopher P Tinworth2, Iain Uings1, Justyna Wojno-Picon2, Robert J Young2, Efstratios Stratikos4.   

Abstract

ER aminopeptidase 1 (ERAP1) is an intracellular enzyme that generates antigenic peptides and is an emerging target for cancer immunotherapy and the control of autoimmunity. ERAP1 inhibitors described previously target the active site and are limited in selectivity, minimizing their clinical potential. To address this, we targeted the regulatory site of ERAP1 using a high-throughput screen and discovered a small molecule hit that is highly selective for ERAP1. (4aR,5S,6R,8S,8aR)-5-(2-(Furan-3-yl)ethyl)-8-hydroxy-5,6,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid is a natural product found in Dodonaea viscosa that constitutes a submicromolar, highly selective, and cell-active modulator of ERAP1. Although the compound activates hydrolysis of small model substrates, it is a competitive inhibitor for physiologically relevant longer peptides. Crystallographic analysis confirmed that the compound targets the regulatory site of the enzyme that normally binds the C-terminus of the peptide substrate. Our findings constitute a novel starting point for the development of selective ERAP1 modulators that have potential for further clinical development.

Entities:  

Year:  2020        PMID: 32109056     DOI: 10.1021/acs.jmedchem.9b02123

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Conformational remodeling enhances activity of lanthipeptide zinc-metallopeptidases.

Authors:  Chang Zhao; Wangjian Sheng; Ying Wang; Jie Zheng; Xiangqian Xie; Yong Liang; Wanqing Wei; Rui Bao; Huan Wang
Journal:  Nat Chem Biol       Date:  2022-05-05       Impact factor: 16.174

2.  ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.

Authors:  Silvia D'Amico; Valerio D'Alicandro; Mirco Compagnone; Patrizia Tempora; Giusy Guida; Paolo Romania; Valeria Lucarini; Ombretta Melaiu; Michela Falco; Mattia Algeri; Daniela Pende; Loredana Cifaldi; Doriana Fruci
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

3.  Discovery of Selective Inhibitor Leads by Targeting an Allosteric Site in Insulin-Regulated Aminopeptidase.

Authors:  Ioannis Temponeras; Lykourgos Chiniadis; Athanasios Papakyriakou; Efstratios Stratikos
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

4.  ERAP1 binds peptide C-termini of different sequences and/or lengths by a common recognition mechanism.

Authors:  Lufei Sui; Hwai-Chen Guo
Journal:  Immunobiology       Date:  2021-07-04       Impact factor: 3.152

5.  Common allotypes of ER aminopeptidase 1 have substrate-dependent and highly variable enzymatic properties.

Authors:  Jonathan P Hutchinson; Ioannis Temponeras; Jonas Kuiper; Adrian Cortes; Justyna Korczynska; Semra Kitchen; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2021-02-19       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.